JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) - USD ($)				1 Months Ended						12 Months Ended		65 Months Ended
	Aug. 11, 2017	Jul. 14, 2017	Aug. 03, 2012	Oct. 27, 2017	Aug. 31, 2017	Aug. 31, 2016	Aug. 25, 2016	Jun. 01, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017
Related Party Transaction [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			$ 6,000,000							$ 6,000,000		$ 6,000,000
Joint Venture Investments In Voting Common Ownership Units (in shares)			600,000
Joint Venture Investments In Non Voting Preferred Ownership Units			5,000,000
Development Activities Monthly Fee			$ 63,000
Joint Venture, Operating Expenses, Inter Company Transactions										1,179,000		9,651,000
Joint Venture, Operating Expenses Allocated To Company												8,039,000
Percentage Of Non Royalty Income			5.00%
Conversion of Stock, Shares Converted	3,500,000								1,500,000
Conversion of Stock, Shares Issued									120,000
Joint Venture Method Investment Ownership Percentage			60.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							33,088
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 10.70
Management Fees								$ 80,000
Professional Fees								$ 10,000
Operating Expenses Net Of Elimination Of Intercompany Transactions										1,179,000
Conversion of Stock, Amount Converted	$ 3,500,000
Conversion of Stock, Amount Issued	$ 1,000,000
Interest Payable										68,000		68,000
Other Assets, Current										$ 98,000	$ 131,000	$ 98,000
Accrued Professional Fees					$ 20,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant										83,480		83,480
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										0	280,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price										$ 0	$ 0.86
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage										50.00%
Mr Holliman [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				14,126
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 10.70
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period										5 years
Ownership As Converted [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage										65.11%
Ownership As Converted Including Options And Warrants [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage				64.31%
Series B1 Preferred Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Losses Recognition Criteria, Common Ownership Equity							$ 946,000
Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs							1,012,000
Proceeds from Issuance of Preferred Stock and Preference Stock						$ 946,000	946,000			$ 0	$ 946,000
Payments of Stock Issuance Costs							$ 66,000
Stock Issued During Period, Shares, New Issues							94,537
Management Fees					$ 300,000						300,000
Professional Fees											60,000
Management Fee Expense										150,000	250,000
Other Assets, Current											50,000
Accrued Professional Fees										100,000		$ 100,000
Other Commitment, Due in Second Year										150,000		150,000
Series B2 Preferred Stock [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock										(15,000)	$ 0
Payments of Stock Issuance Costs		$ 287,000
Stock Issued During Period, Shares, Acquisitions	93,458				93,458		93,458
Stock Issued During Period, Value, Acquisitions	$ 1,000,000				$ 1,000,000		$ 1,000,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 15,000
Series B Preferred Stock [Member] | Preferred Stock And Warrant Purchase Agreement [Member]
Related Party Transaction [Line Items]
Preferred Stock, Dividend Rate, Percentage							5.00%
Series B1 And B2 Preferred Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage			62.20%				62.20%
Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage			69.75%
Revolving Credit Facility [Member]
Related Party Transaction [Line Items]
Long-term Line of Credit										1,640,000		1,640,000
Interest Payable										40,000		40,000
Common Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Losses Recognition Criteria, Common Ownership Equity										$ 0		$ 0
Stock Issued During Period, Shares, New Issues										13,500,000
Preferred Stock [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent										100.00%		100.00%
Noncontrolling Interest [Member]
Related Party Transaction [Line Items]
Noncash or Part Noncash Acquisition, Other Liabilities Assumed												$ 667,000
Maximum [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage									64.00%
Minimum [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage									60.00%
Exclusive License Agreement [Member]
Related Party Transaction [Line Items]
Percentage Of Royalty Payment			3.00%
Annual Maintenance Payments			$ 25,000
Exclusive License Agreement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Milestone Payments			500,000
Royalty Expense			1,000,000
Exclusive License Agreement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Milestone Payments			50,000
Royalty Expense			$ 500,000
Lipimetix [Member]
Related Party Transaction [Line Items]
Joint Venture Investments Common Ownership Units, Co-venture (in shares)			400,000
Ownership Percentage Co-venture			40.00%
Noncash or Part Noncash Acquisition, Other Liabilities Assumed										$ 667,000
Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed), Total			$ 378,000							$ 378,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										81,479
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price										$ 1.07
Voting Common Ownership Units [Member]
Related Party Transaction [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			1,000,000
Non Voting Preferred Ownership Units [Member]
Related Party Transaction [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			$ 5,000,000